Aaron Wealth Advisors LLC Increases Stock Position in Johnson & Johnson $JNJ

Aaron Wealth Advisors LLC grew its stake in shares of Johnson & Johnson (NYSE:JNJ) by 15.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 41,305 shares of the company’s stock after acquiring an additional 5,473 shares during the quarter. Aaron Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $8,548,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. Abich Financial Wealth Management LLC purchased a new position in shares of Johnson & Johnson in the third quarter worth approximately $26,000. Evolution Wealth Management Inc. purchased a new position in shares of Johnson & Johnson in the second quarter worth approximately $27,000. Clayton Financial Group LLC purchased a new position in shares of Johnson & Johnson in the third quarter worth approximately $28,000. Semmax Financial Advisors Inc. raised its stake in Johnson & Johnson by 55.0% during the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after acquiring an additional 72 shares during the period. Finally, Turning Point Benefit Group Inc. bought a new stake in Johnson & Johnson during the 3rd quarter worth approximately $41,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 0.1%

Johnson & Johnson stock opened at $241.13 on Friday. The stock has a market cap of $580.78 billion, a P/E ratio of 21.82, a PEG ratio of 2.39 and a beta of 0.34. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.77. Johnson & Johnson has a 1 year low of $145.13 and a 1 year high of $251.71. The firm’s 50 day moving average price is $241.07 and its 200-day moving average price is $214.54.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. The firm had revenue of $24.28 billion for the quarter. On average, equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: TD Cowen reiterated a Buy and set a $250 price target, underpinning near-term upside expectations from improving fundamentals and pipeline momentum. TD Cowen Buy, $250 PT
• Positive Sentiment: Citi and other brokers have raised price targets and highlighted J&J’s stronger MedTech outlook, supporting bullish analyst sentiment that could prop the shares if Q1 confirms recovery. Citigroup Forecasts Strong Price Appreciation for JNJ
• Positive Sentiment: J&J launched the VARIPULSE Pro pulsed field ablation system in Europe (CE mark), adding a potential growth driver for its MedTech segment as real‑world studies and conference data are collected. This rollout is a concrete revenue catalyst if adoption scales. Johnson & Johnson PFA Launch Puts VARIPULSE Pro And Valuation In Focus
• Neutral Sentiment: Coverage pieces in Barron’s and TipRanks emphasize the rebound narrative heading into earnings, raising visibility but not adding new fundamental proof — they may support sentiment but won’t move the stock without data. Buy Johnson & Johnson Ahead of Earnings
• Neutral Sentiment: Market / media mentions (lists, S&P visibility) and multiple analyst notes increase attention; these can amplify moves but are secondary to earnings and device adoption. JNJ Gains Visibility As S&P 500 Trends Shift
• Negative Sentiment: Zacks warns that rising biosimilar competition and pricing pressure remain material headwinds for J&J’s pharma business; those risks mean the upcoming Q1 print could produce downside if guidance or growth details disappoint. Should You Buy, Sell or Hold JNJ Ahead of Q1
• Negative Sentiment: Upcoming Q1 estimates and metric expectations introduce short‑term volatility: if reported drug growth or MedTech momentum falls short of elevated analyst hopes, the stock could underperform. Wall Street Estimates for JNJ Q1

Analyst Ratings Changes

JNJ has been the topic of a number of recent analyst reports. Bank of America restated a “neutral” rating on shares of Johnson & Johnson in a research note on Monday, March 2nd. Daiwa Securities Group raised their target price on shares of Johnson & Johnson from $203.00 to $237.00 and gave the stock an “outperform” rating in a research note on Thursday, January 29th. JPMorgan Chase & Co. raised their target price on shares of Johnson & Johnson from $225.00 to $250.00 and gave the stock a “neutral” rating in a research note on Thursday, March 5th. Wolfe Research raised their target price on shares of Johnson & Johnson from $225.00 to $240.00 and gave the stock an “outperform” rating in a research note on Monday, January 5th. Finally, Scotiabank restated an “outperform” rating on shares of Johnson & Johnson in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $237.57.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 6,197 shares of Johnson & Johnson stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the transaction, the executive vice president directly owned 23,003 shares of the company’s stock, valued at $5,598,700.17. The trade was a 21.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Timothy Schmid sold 22,623 shares of Johnson & Johnson stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the transaction, the executive vice president directly owned 26,769 shares of the company’s stock, valued at $6,540,469.77. The trade was a 45.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 30,142 shares of company stock valued at $7,360,528. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.